Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05144464
Other study ID # JSVCT122
Secondary ID
Status Enrolling by invitation
Phase Phase 4
First received
Last updated
Start date September 19, 2021
Est. completion date April 30, 2022

Study information

Verified date March 2022
Source Jiangsu Province Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For those aged 6 months through 8 years who have previously received ≥2 total doses of trivalent or quadrivalent influenza vaccine ≥4 weeks apart, they require only 1 dose of influenza vaccine. For those who have not previously received ≥2 doses of trivalent or quadrivalent influenza vaccine, they require 2 dose of influenza vaccine. but the evidence on how to select vaccine doses for quadrivalent influenza vaccine is limited in China. The study is a prospective, open-label comparison of the immunogenicity and reactogenicity of 1 versus 2 doses of an inactivated quadrivalent influenza vaccine in subjects of 3-8 years old with different history of influenza vaccination.


Description:

Subjects receive 2 dosed of quadrivalent influenza vaccine 4 weeks apart. Blood samples were obtained from children at 3 time points-before receipt of dose 1, 4 weeks after receipt of dose 1 and before dose 2, and 4 weeks after dose 2. Hemagglutination inhibition (HAI) antibody titers to the A/H3N2, A/H1N1, and B antigens included in the vaccine were measured at each time point


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 240
Est. completion date April 30, 2022
Est. primary completion date November 23, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years to 8 Years
Eligibility Inclusion Criteria: - Aged 3-8 years old - Healthy subjects judged from medical history and clinical examination - Subjects themselves or their guardians able to understand and sign the informed consent - Subjects themselves or their guardians can and will comply with the requirements of the protocol - Subjects have received =2 doses of trivalent or quadrivalent infuenza vaccine before enrollment (Doses need not have been received during same or consecutive seasons); Subjects have not received infuenza vaccine before enrollment - Subjects with temperature <=37.0°C on axillary setting Exclusion Criteria: - Subject who has a medical or family history of any of the following: allergic history, seizure, epilepsy, brain or mental disease - Subject who is allergic to any ingredient of the vaccine - Subject with damaged or low immune function which has already been known - Subject with acute febrile illness or infectious disease - Major congenital defects or serious chronic illness, including perinatal brain damage - Thrombocytopenia, blood coagulation disorder or bleeding difficulties with intramuscular injection - Subject who has serious allergic history - Subject who developed guillain-Barre syndrome post influenza vaccination - Any prior administration of immunodepressant or corticosteroids in last 6 months - Any prior administration of influenza vaccine in last 6 month - Any prior administration of blood products in last 3 months - Any prior administration of other research medicine/vaccine in last 30 days - Any prior administration of any attenuated live vaccine in last 14 days - Any prior administration of subunit or inactivated vaccines in last 7 days, such as pneumococcal vaccine - Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent for subject's guardian

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Quadrivalent influenza vaccine
Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection

Locations

Country Name City State
China Pizhou City Center for Disease Control and Prevention Xuzhou Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu Province Centers for Disease Control and Prevention Jiangsu Jindike Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Comparision between Seroconversion Rate (SCR) of HAI antibodies against each virus strain post dose 1 and dose 2 The lowest dilution used in the assay is 1/10. Seroconversion was defined as either a pre-vaccination HAI titer < 1:10 and a post-vaccination titer =1:40 or a pre-vaccination titer =1:10 and = four-fold increase in post-vaccination titer. day 28 after receipt of dose 1 and before dose 2, and day 28 after dose 2.
Other Comparision between Geometric Mean Titre (GMT) of HAI antibodies against each virus strain post dose 1 and dose 2 day 28 after receipt of dose 1 and before dose 2, and day 28 after dose 2.
Other Comparision between seroprotection rates of HAI antibodies against each virus strain post dose 1 and dose 2 A seroprotected subject is defined as a vaccinated subject with serum HAI titer= 1:40. day 28 after receipt of dose 1 and before dose 2, and day 28 after dose 2.
Other Comparision between Geometric Mean Fold Increase (GMFI) of HAI antibodies against each virus strain post dose 1 and dose 2 Hemagglutination inhibition (HAI) titers were used to calculate post-vaccination geometric mean fold increase (GMFI) against each virus strain day 28 after receipt of dose 1 and before dose 2, and day 28 after dose 2.
Primary the 95% confidence interval (CI) lower limit for Seroconversion Rate (SCR) of Hemagglutination inhibition (HAI) antibodies against each virus strain after 2nd vaccination =40% The lowest dilution used in the assay is 1/10. Seroconversion was defined as either a pre-vaccination HAI titer < 1:10 and a post-vaccination titer =1:40 or a pre-vaccination titer =1:10 and = four-fold increase in post-vaccination titer. day 28 after dose 2
Primary Number of participants with Adverse Reactions (ARs) Frequency and severity of ARs for 28 days after each vaccination 28 days after each vaccination
Secondary the 95% CI lower limit for seroprotection rates of HAI antibodies against each virus strain after 2nd vaccination=70% A seroprotected subject is defined as a vaccinated subject with serum HAI titer= 1:40. day 28 after dose 2
Secondary Geometric Mean Fold Increase (GMFI) of HAI titer against each virus strain after 2nd vaccination>2.5 Hemagglutination inhibition (HAI) titers were used to calculate post-vaccination geometric mean fold increase (GMFI) against each virus strain day 28 after dose 2
Secondary Number of participants with Adverse Events (AEs) Frequency and severity of AEs for 28 days after each vaccination 28 days after each vaccination
Secondary Number of participants with Serious Adverse Events (SAE) Frequency of SAEs for 6 months after the last vaccination 6 months after the last vaccination
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A